Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OncoCyte Corporation (OCX : NSDQ)

• Company Description    OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. Number of Employees: 110

• Price / Volume Information    Yesterday's Closing Price: $1.14 Daily Weekly Monthly 20 Day Moving Average: 595,426 shares Shares Outstanding: 99.94 (millions) Market Capitalization: $113.93 (millions) Beta: 1.87 52 Week High: $6.25 52 Week Low: $1.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.00% 7.97% 12 Week -13.64% -6.99% Year To Date -47.47% -36.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15 CUSHING - IRVINE,CA 92618 USA ph: 949-409-7600 fax: 510-521-3389 bob@lifesciadvisors.com http://www.oncocyte.com

• General Corporate Information    Officers Ronald Andrews - President and Chief Executive Officer Li Yu - Vice President and Controller Mitchell Levine - Chief Financial Officer Melinda Griffith - Director Andrew Arno - Director Peer Information OncoCyte Corporation (CHCR) OncoCyte Corporation (ESRX) OncoCyte Corporation (MYDP) OncoCyte Corporation (GBCS) OncoCyte Corporation (LAXAF) OncoCyte Corporation (IPCM) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Medical Services Sector: Medical CUSIP: 68235C107 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 99.94 Most Recent Split Date: (:1) Beta: 1.87 Market Capitalization: $113.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.52 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.00 Price/Cash Flow: - Price / Sales: 14.19 EPS Growth vs. Year Ago Period: -175.00% vs. Previous Quarter: 8.33% Sales Growth vs. Year Ago Period: 26.78% vs. Previous Quarter: -60.30% ROE 03/31/22 - -52.12 12/31/21 - -37.25 09/30/21 - -35.36 ROA 03/31/22 - -25.93 12/31/21 - -21.94 09/30/21 - -22.81 Current Ratio 03/31/22 - 1.76 12/31/21 - 2.77 09/30/21 - 3.56 Quick Ratio 03/31/22 - 1.76 12/31/21 - 2.77 09/30/21 - 3.56 Operating Margin 03/31/22 - -526.22 12/31/21 - -450.52 09/30/21 - -651.63 Net Margin 03/31/22 - -877.80 12/31/21 - -829.52 09/30/21 - -743.83 Pre-Tax Margin 03/31/22 - -898.93 12/31/21 - -949.37 09/30/21 - -948.89 Book Value 03/31/22 - 0.57 12/31/21 - 0.71 09/30/21 - 1.08 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.18

Powered by Zacks Investment Research ©